Abstract
Three major advances over the last decade have impacted the way we treat rheumatoid arthritis; early and aggressive treatment, use of disease activity measures leading to treat to target, and availability of biologic agents. No oral biologic agents are available at this time but promising data is emerging for two drugs, tofacitinib and fostamatinib, inhibitors of JAK and Syk kinases, respectively. This paper will review some of the relevant published data for these agents and discuss where they may be placed in our treatment options for RA.
MeSH terms
-
Aminopyridines
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / enzymology
-
Humans
-
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
-
Intracellular Signaling Peptides and Proteins / metabolism
-
Janus Kinases / antagonists & inhibitors*
-
Janus Kinases / metabolism
-
Morpholines
-
Oxazines / adverse effects
-
Oxazines / therapeutic use*
-
Piperidines
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Protein-Tyrosine Kinases / metabolism
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use*
-
Pyrroles / adverse effects
-
Pyrroles / therapeutic use*
-
Syk Kinase
-
Treatment Outcome
Substances
-
Aminopyridines
-
Antirheumatic Agents
-
Intracellular Signaling Peptides and Proteins
-
Morpholines
-
Oxazines
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyridines
-
Pyrimidines
-
Pyrroles
-
tofacitinib
-
Protein-Tyrosine Kinases
-
Janus Kinases
-
SYK protein, human
-
Syk Kinase
-
fostamatinib